A5010759463- Cancer Genomics and Diagnostics
- Ocular Oncology and Treatments
- Cancer Cells and Metastasis
- Advanced biosensing and bioanalysis techniques
- Nanoplatforms for cancer theranostics
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- CRISPR and Genetic Engineering
- Monoclonal and Polyclonal Antibodies Research
- Chromosomal and Genetic Variations
- Angiogenesis and VEGF in Cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced Breast Cancer Therapies
- NF-κB Signaling Pathways
- Estrogen and related hormone effects
- Axon Guidance and Neuronal Signaling
- Parvovirus B19 Infection Studies
- Cancer-related gene regulation
- Hedgehog Signaling Pathway Studies
- MRI in cancer diagnosis
- Cancer Research and Treatments
- Renal cell carcinoma treatment
Institut Curie
2013-2024
Inserm
2011-2024
Université Paris Sciences et Lettres
2017-2022
Université Paris Cité
2011-2014
Délégation Paris 7
2012-2014
Délégation Paris 6
2013
Sorbonne Paris Cité
2012
Hôpital Lariboisière
2010-2011
Institut des Vaisseaux et du Sang
2010
Université Paris-Saclay
2009
Recent clinical results support the use of new immune checkpoint blockers (ICB), such as anti-PD-1 (e.g. nivolumab and pembrolizumab) anti-PD-L1 antibodies. Radiological evaluation ICB efficacy during therapy is challenging due to tumor infiltration. Changes circulating DNA (ctDNA) levels could be a promising tool for very accurate monitoring treatment efficacy, but data are lacking with ICB.This prospective pilot study was conducted in patients nonsmall cell lung cancer, uveal melanoma, or...
In nonmetastatic triple-negative breast cancer (TNBC) patients, we investigated whether circulating tumor DNA (ctDNA) detection can reflect the response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery.Ten milliliters of plasma were collected at 4 time points: before NCT; 1 cycle; surgery; surgery. Customized droplet digital PCR (ddPCR) assays used track protein p53 (TP53) mutations previously characterized in tissue by massively parallel sequencing...
Circulating tumor cells (CTCs) and circulating DNA (ctDNA) have been recently investigated in several cancer types, but their respective clinical significance remains to be determined. In our prospective study, we compared the detection rate prognostic value of these two biomarkers patients with metastatic uveal melanoma. GNAQ/GNA11 mutations were characterized archived tissue. Using a highly sensitive mutation‐specific bidirectional pyrophosphorolysis‐activated polymerization (bi‐PAP)...
Metastatic uveal melanoma is a deadly disease with no proven standard of care. Here we present metastatic patient an exceptional high sensitivity to PD-1 inhibitor associated outlier CpG>TpG mutation burden, MBD4 germline deleterious mutation, and somatic inactivation in the tumor. We identify additional tumors The Cancer Genome Atlas (TCGA) cohorts similar hypermutator profiles patients carrying mutations loss heterozygosity. This MBD4-related phenotype may explain unexpected responses...
The management of patients with colorectal cancer (CRC) and potentially resectable liver metastases (LM) requires quick assessment mutational status response to pre-operative systemic therapy. In a prospective phase II trial (NCT01442935), we investigated the clinical validity circulating tumor cell (CTC) DNA (ctDNA) detection. CRC LM were treated first-line triplet or doublet chemotherapy combined targeted CTC (Cellsearch®) Kirsten RAt Sarcoma (KRAS) ctDNA (droplet digital polymerase chain...
Abstract Purpose: To develop a molecular tool to detect circulating tumor–derived DNA (ctDNA) in the plasma from patients with uveal melanoma as marker of tumor burden and monitor treatment efficacy. Experimental Design: A real-time PCR was developed on basis bidirectional pyrophosphorolysis-activated polymerization (bi-PAP) for quantification ctDNA using 3′blocked primer pairs specific 3 recurrent mutually exclusive mutations Gα subunits GNAQ GNA11. Results: Sensitivity specificity bi-PAP...
Abstract Circulating tumor cells (CTCs) and circulating DNA (ctDNA) are two cancer-derived blood biomarkers that inform on patient prognosis treatment efficacy in breast cancer. We prospectively evaluated the clinical validity of quantifying both CTCs (CellSearch) ctDNA (targeted next-generation sequencing). Their combined value as prognostic early monitoring markers was assessed 198 HER2-negative metastatic cancer patients. All patients were included prospective multicenter UCBG study COMET...
Abstract Background CirCe01 trial aimed to assess the clinical utility of circulating tumour cell (CTC)-based monitoring in metastatic breast cancer (MBC) patients beyond third line chemotherapy (LC). Methods was a prospective, multicentre, randomised (NCT01349842) that included with MBC after two systemic LC. Patients ≥5 CTC/7.5 mL (CellSearch®) were between CTC-driven and standard arm. In CTC arm, changes count assessed at first cycle each LC; whom levels predicted early progression had...
<p>Fig S9. Age has a minor effect on L1PA DNA methylation patterns and is not confounding factor in this study</p>
<p>Fig S5. Comparison of tumor and plasma paired samples</p>
<p>Fig S8. DIAMOND profiles and performances in the validation versus discovery cohorts</p>
<p>Fig S11. 2 step-models integrating CNA signal extracted from DIAMOND data</p>
<p>Fig S6. Classifier performances: feature types, calculation parameters, cancer subtypes and stages</p>
<p>Fig S8. DIAMOND profiles and performances in the validation versus discovery cohorts</p>
<p>Fig S10. Comparison of multiple classifiers (expert, all, stack and blind models) prognostic value L1PA hypomethylation</p>
<p>Fig S5. Comparison of tumor and plasma paired samples</p>
<p>Fig S3. Preparation of L1PA targeted bisulfite sequencing libraries and analysis workflow</p>
<p>Fig S1. cfDNA extraction methods did not impact the L1PA methylation patterns</p>
<p>Fig S9. Age has a minor effect on L1PA DNA methylation patterns and is not confounding factor in this study</p>
<p>Fig S4. DIAMOND features: CpG calling and contribution of CG positions or haplotypes</p>
<p>Fig S2. Methylation profiles obtained with bisulfite or enzymatic conversion are similar</p>
<div>AbstractPurpose:<p>The detection of ctDNA, which allows noninvasive tumor molecular profiling and disease follow-up, promises optimal individualized management patients with cancer. However, detecting small fractions DNA released when the burden is reduced remains a challenge.</p>Experimental Design:<p>We implemented new, highly sensitive strategy to detect bp resolution methylation patterns from plasma assessed potential hypomethylation long interspersed nuclear...
<p>Fig S6. Classifier performances: feature types, calculation parameters, cancer subtypes and stages</p>